

IN THE DISCLOSURE

The Examiner is requested to amend the specification by inserting before the first line the sentence -- "This application is a continuation of application number 08/558,472, filed November 16, 1995, (status: allowed).-- now US Patent 6,083,835, which claims the priority of CA 2155910, filed Aug. 11, 1995.

5/28/04

At page 1, line 25, after 'by' and before 'Patent', please insert ---US---.

At page 2, line 21, please delete "(Weiczorowska, K. et al Short Reports?)" and insert ---(Wieczorowska, K. et al. Perit. Dial. Int. 15:81, 1995)---.

At page 2, line 29, please delete "glycosoaminoglycans" and insert --- glycosaminoglycans---.

At page 2, lines 32 to 33, after 'peritoneal' please delete "leucocytes" and insert ---leukocytes---.

At page 4, line 16, after 'removal' please delete ";".

At page 5, line 7, please delete "S. marcescens" and insert --S. marcescens---.

At page 5, line 15, please delete "Patent 5, 011,826" and insert ---US Patent 5,011,826---.

At page 5, line 17, after 'whereas' please insert ---US---.

At page 5, line 19, after 'well' please delete "patent" and insert ---US Patent---.

At page 5, lines 25 to 26, after 'solution' please delete "(Kidney Int 46: 496, 1994; US Patent 4,886,789)" and insert ---(Kidney Int. 46: 496, 1994; US Patent 4,886,789)---.

S.C.
THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

What is claimed is:

6/28/04

1. A peritoneal dialysis solution which comprises a water solution with a pH compatible with the intended use of the product, with electrolytes, including sodium, chloride, calcium and magnesium of a suitable and compatible compositions and one or a combination of acetylated or deacetylated amino sugars, such as glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine, N-acetylmannosamine as monomers or oligomers of 2 to 12 carbohydrate units alone or in combination with glucose and/or sodium lactate, malate, acetate, succinate and/or iduronid acid and/or glucuronic acid.
2. The solution of claim 1 in which the pH is in the range of 5 – 7.4 and the sodium concentration is present in the range of 115 – 140 mEquiv/L, calcium is present in the range of 0.6 mEquiv/L, chloride is present in the range of 100 – 145 mEquiv/L, magnesium is present in the range of 0 – 2 mEquiv/L, lactate, malate, acetate or succinate in the range of 30 – 45 mEquiv/L.
3. The solution of claim 1 in which the osmotically active agent is and amino sugar taken from the following group of compounds of glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine or N-acetylmannosamine.
4. The solution of claim 3 in which the osmotically active agents are present at a concentration of 0.5 – 5.0 % (w/v).
5. The solution of claim 3 of which the osmotically active agents are present at the concentrations specified in claim 4 together with glucose at a concentration of 0.5 to 5.0% (w/v).
6. The solution of claim 1 in which the osmotically active agents are present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.
7. A peritoneal dialysis solution comprising an effective amount of an acetylate or deacetylated amino sugar and/or combinations thereof.